Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future

Overview

Journal J Parkinsons Dis

Publisher Sage Publications

Specialty Neurology

Date 2021 Dec 27

PMID 34957948

Citations 48

Authors

Yu-Yan Tan

Peter Jenner

Sheng-di Chen

Affiliations

Soon will be listed here.

Abstract

Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson's disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as adjuvant drugs have been widely applied for the treatment of the advanced stages of the illness. MAO-B inhibitors can effectively improve patients' motor and non-motor symptoms, reduce "OFF" time, and may potentially prevent/delay disease progression. In this review, we discuss the effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy.

Citing Articles

Flavonoids and Saponins from Two Species ( Asch. and - L.)-Preliminary Evaluation for hMAO-A/B, Neuroprotective Activity, and Validated UHPLC-HRMS Quantification of Ethanolic Extract from .

Kondeva-Burdina M, Panayotova D, Nedialkov P, Kokanova-Nedialkova Z Molecules. 2025; 30(5).

PMID: 40076286 PMC: 11901915. DOI: 10.3390/molecules30051061.

Advances in the study of depression and anxiety in Parkinson's disease: A review.

Wang Z, Wei H, Xin Y, Qin W Medicine (Baltimore). 2025; 104(10):e41674.

PMID: 40068027 PMC: 11903018. DOI: 10.1097/MD.0000000000041674.

Neuroprotective efficacy of berberine and caffeine against rotenone-induced neuroinflammatory and oxidative disturbances associated with Parkinson's disease via inhibiting α-synuclein aggregation and boosting dopamine release.

Waheeb T, Abdulkader M, Ghareeb D, Moustafa M Inflammopharmacology. 2025; .

PMID: 40057928 DOI: 10.1007/s10787-025-01661-w.

Exploring the active ingredients and potential mechanisms of Pingchan granules in Parkinson's disease treatment through network pharmacology and transcriptomics.

Xu Q, Wang Y, Wang C, Jiang S, Zhang B, Tian J Sci Rep. 2025; 15(1):7847.

PMID: 40050654 PMC: 11885611. DOI: 10.1038/s41598-025-91344-x.

Progress and prospects of Parkinson's disease with depression research: A global bibliometric analysis based on CiteSpace.

Li J, You J, Li Z, Zang J, Wu L, Zhao T Medicine (Baltimore). 2025; 104(7):e41537.

PMID: 39960944 PMC: 11835133. DOI: 10.1097/MD.0000000000041537.

References

Gomez-Lopez A, Sanchez-Sanchez A, Natera-Villalba E, Ros-Castello V, Beltran-Corbellini A, Fanjul-Arbos S . SURINPARK: Safinamide for Urinary Symptoms in Parkinson's Disease. Brain Sci. 2021; 11(1). PMC: 7825064. DOI: 10.3390/brainsci11010057. View

Sadeghian M, Mullali G, Pocock J, Piers T, Roach A, Smith K . Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease. Neuropathol Appl Neurobiol. 2015; 42(5):423-35. DOI: 10.1111/nan.12263. View

Hattori N, Takeda A, Takeda S, Nishimura A, Kato M, Mochizuki H . Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study. Parkinsonism Relat Disord. 2018; 53:21-27. DOI: 10.1016/j.parkreldis.2018.04.025. View

Myllyla V, Sotaniemi K, Vuorinen J, Heinonen E . Selegiline as initial treatment in de novo parkinsonian patients. Neurology. 1992; 42(2):339-43. DOI: 10.1212/wnl.42.2.339. View

Pagonabarraga J, Arbelo J, Grandas F, Luquin M, Martinez Martin P, Rodriguez-Oroz M . A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice. Brain Sci. 2020; 10(3). PMC: 7139287. DOI: 10.3390/brainsci10030176. View

. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002; 59(12):1937-43. DOI: 10.1001/archneur.59.12.1937. View

Zhang Z, Shao M, Chen S, Liu C, Peng R, Li Y . Adjunct rasagiline to treat Parkinson's disease with motor fluctuations: a randomized, double-blind study in China. Transl Neurodegener. 2018; 7:14. PMC: 6026338. DOI: 10.1186/s40035-018-0119-7. View

Stocchi F, Rabey J . Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Eur J Neurol. 2011; 18(12):1373-8. DOI: 10.1111/j.1468-1331.2011.03512.x. View

Mancini M, Bloem B, Horak F, Lewis S, Nieuwboer A, Nonnekes J . Clinical and methodological challenges for assessing freezing of gait: Future perspectives. Mov Disord. 2019; 34(6):783-790. PMC: 7105152. DOI: 10.1002/mds.27709. View

10.

Hayes M . Parkinson's Disease and Parkinsonism. Am J Med. 2019; 132(7):802-807. DOI: 10.1016/j.amjmed.2019.03.001. View

11.

Gardoni F, Morari M, Kulisevsky J, Brugnoli A, Novello S, Pisano C . Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia. J Pharmacol Exp Ther. 2018; 367(3):442-451. DOI: 10.1124/jpet.118.251645. View

12.

Huang Y, Chen J, Loh E, Chan L, Hong C . The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson's disease: meta-analysis of randomized controlled trials. Ther Adv Psychopharmacol. 2021; 11:2045125320985993. PMC: 7816524. DOI: 10.1177/2045125320985993. View

13.

Naoi M, Maruyama W, Shamoto-Nagai M . Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease. J Neural Transm (Vienna). 2020; 127(2):131-147. DOI: 10.1007/s00702-020-02150-w. View

14.

Calzetti S, Negrotti A, Cassio A . L-deprenyl as an adjunct to low-dose bromocriptine in early Parkinson's disease: a short-term, double-blind, and prospective follow-up study. Clin Neuropharmacol. 1995; 18(3):250-7. DOI: 10.1097/00002826-199506000-00005. View

15.

Meier-Davis S, Dines K, Arjmand F, Hamlin R, Huang B, Wen J . Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo. Cutan Ocul Toxicol. 2012; 31(4):312-7. DOI: 10.3109/15569527.2012.676119. View

16.

Heinonen E, Myllyla V . Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf. 1998; 19(1):11-22. DOI: 10.2165/00002018-199819010-00002. View

17.

Alborghetti M, Nicoletti F . Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside. Curr Neuropharmacol. 2018; 17(9):861-873. PMC: 7052841. DOI: 10.2174/1570159X16666180830100754. View

18.

Schapira A, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P . Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Eur J Neurol. 2012; 20(2):271-80. DOI: 10.1111/j.1468-1331.2012.03840.x. View

19.

Hattori N, Takeda A, Takeda S, Nishimura A, Kitagawa T, Mochizuki H . Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease. J Neural Transm (Vienna). 2019; 126(3):299-308. PMC: 6449288. DOI: 10.1007/s00702-018-1964-3. View

20.

Seidl S, Potashkin J . The promise of neuroprotective agents in Parkinson's disease. Front Neurol. 2011; 2:68. PMC: 3221408. DOI: 10.3389/fneur.2011.00068. View